Optimizing Cardiovascular Health During Testosterone Therapy: Comprehensive Strategies for TRT Hematocrit Management and Beyond

Testosterone replacement therapy (TRT) offers many men renewed vitality, improved body composition, and enhanced well-being—but it also brings important responsibilities. One of the most discussed considerations in ongoing TRT is the management of hematocrit, the proportion of red blood cells in your blood. Why does TRT increase hematocrit, what are the potential risks, and how can individuals optimize cardiovascular health while reaping the benefits of hormone therapy?

This guide explores the science of TRT hematocrit management, reviews the latest research, and provides practical, evidence-based strategies for optimizing heart health throughout your hormone optimization journey.

In this article, you'll learn:

• Why TRT affects hematocrit and cardiovascular health

• The best practices for monitoring and managing hematocrit during therapy

• Current research on risks, benefits, and safe thresholds

• How to personalize your TRT plan for long-term success

Table of Contents

1. Understanding Hematocrit and TRT

2. TRT, Erythrocytosis, and Cardiovascular Health

3. The Biological Mechanisms Behind TRT-Induced Erythrocytosis

4. Evidence-Based Strategies for Safe TRT Hematocrit Management

5. Addressing Elevated Hematocrit: Personalized Approaches

6. Latest Research and Trends in TRT Hematocrit Management

7. Potential Side Effects and Safety Considerations

8. Taking Action: How to Optimize Your TRT Journey

9. Frequently Asked Questions

10. References

1. Understanding Hematocrit and TRT

Hematocrit reflects the proportion of red blood cells in your blood. Normal ranges vary, but elevations above 50–54% are considered significant and may warrant intervention, especially in men on testosterone therapy (Cervi & Balitsky, 2017). TRT is increasingly prescribed for men with symptoms of testosterone deficiency, offering improvements in mood, energy, muscle mass, and body composition (Dobs & Campbell, 2022). However, one of the most common and predictable side effects is an increase in hematocrit—a phenomenon called erythrocytosis.

Routine hematocrit monitoring is essential for anyone on TRT, as unrecognized elevations may increase blood viscosity and potentially impact cardiovascular health. Guidelines recommend baseline and periodic monitoring to ensure safe and effective therapy (Basheer et al., 2025).

2. TRT, Erythrocytosis, and Cardiovascular Health

TRT-induced erythrocytosis is dose-related and varies with the route of administration. Intramuscular injections, particularly short-acting forms, are associated with the highest risk, while transdermal and topical preparations pose a lower risk (Ohlander et al., 2017). Notably, even modest increases in hematocrit can have clinical implications, especially for individuals with other cardiovascular risk factors such as diabetes, obesity, or a history of vascular disease (Liu et al., 2025).

While there is theoretical concern that higher hematocrit could increase the risk of clotting events (such as deep vein thrombosis or stroke), major clinical trials and systematic reviews have not established a clear causal link between well-managed TRT and increased cardiovascular events (Hackett, 2024). Still, vigilance is warranted—especially for those with additional risk factors or hematocrit exceeding guideline thresholds.

3. The Biological Mechanisms Behind TRT-Induced Erythrocytosis

Testosterone stimulates red blood cell production via several mechanisms:

• Suppression of hepcidin, a hormone regulating iron availability, thereby increasing iron for erythropoiesis.

• Transient increases in erythropoietin (EPO), which then settles at a new, higher setpoint.

• Stimulation of erythroid progenitor cells through androgen receptor pathways.

• Aromatization to estradiol, which may also support red cell mass expansion.

These effects are more pronounced with higher doses and injectable forms, and older individuals may experience greater increases due to altered regulatory mechanisms (Bond et al., 2024).

4. Evidence-Based Strategies for Safe TRT Hematocrit Management

Proactive management of hematocrit during TRT is crucial for cardiovascular safety and long-term health optimization. Key strategies include:

• Regular Monitoring: Guideline-recommended intervals are baseline, 3–6 months after starting or changing therapy, then annually. More frequent checks are prudent for those with higher baseline hematocrit or additional risk factors (Basheer et al., 2025).

• Formulation Selection: Consider non-injectable options (gels, patches) for those at higher risk of erythrocytosis.

• Dose Optimization: Use the lowest effective dose to achieve symptom improvement and maintain testosterone in the mid-normal range.

• Address Modifiable Risks: Smoking cessation, treatment of sleep apnea, and management of obesity can all mitigate erythrocytosis risk.

Key Benefits of Individualized TRT Hematocrit Management:

• Reduced Cardiovascular Risk: Well-managed hematocrit may lower the likelihood of thrombotic events and maintain optimal blood flow (Goodale et al., 2017).

• Improved Symptom Relief: Dosage and formulation adjustment can maintain benefits without unnecessary side effects.

• Long-Term Health Optimization: Ongoing monitoring supports broader metabolic and cardiovascular health goals.

5. Addressing Elevated Hematocrit: Personalized Approaches

If hematocrit rises above guideline thresholds (generally 52–54%), options include:

• Reducing the testosterone dose or extending dosing intervals.

• Switching to a lower-risk formulation (e.g., topical instead of injectable).

• Temporarily pausing therapy to allow hematocrit to normalize; levels typically fall within 3–12 months after discontinuation (Ohlander et al., 2017).

• Therapeutic phlebotomy may be considered if other measures are insufficient, but recent research suggests the benefits and risks are not as well established as in primary blood disorders, and it may not always reduce clot risk (Bond et al., 2024).

Ultimately, management should be individualized, weighing symptom improvement, cardiovascular risk, and patient preferences. Lifestyle interventions remain a cornerstone of risk reduction.

6. Latest Research and Trends in TRT Hematocrit Management

Recent large trials, including the TRAVERSE study, confirm that TRT—when carefully managed—does not significantly increase major cardiovascular events, even in those with high baseline risk (Hackett, 2024). Hematocrit elevations were infrequent causes for discontinuation, and when managed within recommended thresholds, did not drive adverse outcomes.

Emerging trends include:

• More widespread use of topical and short-acting formulations to reduce erythrocytosis risk.

• Personalized protocols that consider genetics, comorbidities, and lifestyle factors.

• Data-driven telehealth solutions for ongoing monitoring and expert-guided adjustments—tools that support the comprehensive approach at Marek Health.

Table: TRT Formulation and Risk of Erythrocytosis (adapted from Liu et al., 2025)

• Short-acting IM injections: Highest risk (up to 40%)

• Pellets: Moderate risk (~35%)

• Transdermal gels/patches: Lower risk (12–13%)

• Oral undecanoate: Very low risk (<1%)

7. Potential Side Effects and Safety Considerations

While TRT is generally safe for appropriately selected individuals, some may experience side effects, including increased hematocrit, blood pressure changes, acne, or sleep apnea exacerbation (Basheer et al., 2025). The risk of thrombotic events due to elevated hematocrit appears modest for most, but increases with additional risk factors such as smoking, obesity, or sleep apnea (Bond et al., 2024; Liu et al., 2025).

While these therapies can be beneficial, some individuals may experience side effects. These vary based on individual factors, so we recommend discussing potential risks with your Marek Health provider before starting any new treatment. When you work with Marek Health, our team will work with you to minimize any side effects through personalized protocols and ongoing monitoring.

8. Taking Action: How to Optimize Your TRT Journey

If you are considering testosterone therapy or are already on TRT, prioritizing cardiovascular health and effective hematocrit management is essential. Working with a knowledgeable provider is the best way to ensure safe, personalized care. At Marek Health, our expert clinicians and health coaches guide you through every step—from comprehensive intake and individualized treatment planning to continuous support and monitoring, ensuring your unique goals are met with safety at the forefront.

Sign up for guided optimization with Marek Health to receive a fully individualized approach to hormone optimization, metabolic health, and longevity.

9. Frequently Asked Questions

• What is the ideal hematocrit range for men on TRT?
  Most guidelines recommend maintaining hematocrit below 52–54%. Individual targets may vary based on personal risk factors and provider recommendations (Basheer et al., 2025).

• How often should hematocrit be checked during TRT?
  Typically at baseline, 3–6 months after starting or adjusting therapy, then annually—more frequently if levels approach intervention thresholds (Basheer et al., 2025).

• What are the symptoms of high hematocrit?
  Symptoms may include headache, fatigue, blurred vision, or rarely, more serious complications like clotting events. Many people are asymptomatic—hence the importance of regular monitoring (Cervi & Balitsky, 2017).

• Should I stop TRT if my hematocrit is high?
  Management depends on severity, symptoms, and risk factors. Options include dose reduction, changing formulation, or temporary discontinuation. Always consult with your provider for individualized guidance (Bond et al., 2024).

• Does TRT always cause increased hematocrit?
  Not always, but the risk is highest with injectable forms and higher doses. Other factors, such as age, comorbidities, and genetics, also play a role (Ohlander et al., 2017).

10. References

• Cervi & Balitsky, 2017

• Dobs & Campbell, 2022

• Basheer et al., 2025

• Bond et al., 2024

• Ohlander et al., 2017

• Hackett, 2024

• Goodale et al., 2017

• Liu et al., 2025

This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.